<DOC>
	<DOC>NCT00904371</DOC>
	<brief_summary>The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks. Further on, the study will evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.</brief_summary>
	<brief_title>Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Inclusion criteria: diagnosis of essential arterial hypertension (BP&gt;140/90 mm HG or BP&gt;130/80 mm Hg for diabetic patients) at least an additional cardiovascular risk factor Exclusion criteria: hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market pregnancy and lactation diseases involving biliary obstruction severe liver impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>